Particle.news
Download on the App Store
13 ARTICLES
·
yesterday

CDC Vaccine Panel Evaluates Thimerosal Policy After Faulty Study Citation

Committee members replaced a slide that cited a nonexistent study, prompting senators to seek a delay in deliberations on flu vaccine preservative guidelines.

A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell/File Photo
The entrance to the Centers for Disease Control and Prevention is seen, Tuesday, April 19, 2022, in Atlanta. A decision by a federal judge in Florida to throw out a national mask mandate for public transportation across the U.S. created a confusing patchwork of rules for passengers. The CDC recently extended the mandate, but the court decision put the mandate on hold. (AP Photo/Ron Harris)
People protested in 2005 over a preservative that had been used in vaccines for decades. By 2001, thimerosal had been removed from or reduced in all vaccines routinely recommended for children under 6 in the US.
Image

Overview

  • The CDC’s Advisory Committee on Immunization Practices is meeting June 25–26 to review and potentially vote on recommendations for the preservative thimerosal in influenza vaccines.
  • Lyn Redwood, a former Children’s Health Defense leader, presented slides citing a 2008 Neurotoxicology paper that Robert Berman says does not exist.
  • Robert Berman confirmed he had not authored the cited study, disavowed its findings and the CDC removed the slide in response.
  • HHS Secretary Robert F. Kennedy Jr. replaced all 17 previous vaccine advisers with eight new appointees, including some who have testified against vaccines, raising concerns about the panel’s expertise.
  • Senators Bill Cassidy and Patty Murray urged postponement of the meeting, citing concerns over the committee’s composition and the absence of a confirmed CDC director.